TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7523909

Group type: EXPERIMENTAL
Intervention: Styrene and DCM exposure
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (N=23)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: DCM exposure
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Styrene exposure
Number of subjects: 46
Study: 3258069

Group type: EXPERIMENTAL
Intervention: TENS to appropriate auricular points (Group 1, n = 15)
Number of subjects: 44

Group type: COMPARATOR
Intervention: TENS to inappropriate (placebo) auricular points (Group 2, n = 14)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No TENS (Group 3, n = 15)
Number of subjects: 44
Study: 30044349

Group type: EXPERIMENTAL
Intervention: Modified Faces Pain Scale-Revised (FPS-R)
Number of subjects: 257
Study: 27570858

Group type: EXPERIMENTAL
Intervention: Miswak mouthwash
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Miswak toothpaste
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ordinary toothpaste
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ordinary toothpaste with normal saline
Number of subjects: 40
Study: 26714845

Group type: EXPERIMENTAL
Intervention: Wellness Incentives and Navigation (WIN) project including personal navigators, motivational interviewing, and a flexible wellness account
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Usual care provided within Medicaid Managed Care
Number of subjects: 1250
Study: 23982855

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg lidocaine and 100 % O(2) (group L)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: NaCl and a mixture of 67 % N(2)O/O(2) (group N)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg lidocaine and a mixture of 67 % N(2)O/O(2) (group LN)
Number of subjects: 205

Group type: COMPARATOR
Intervention: NaCl and 100 % O(2) (group C)
Number of subjects: 205
Study: 21761394

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg) + Taurine (2 g)
Number of subjects: 18
Study: 19388924

Group type: EXPERIMENTAL
Intervention: Hybrid simulation model (endovaginal ultrasound task trainer with high-fidelity mannequin)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard high-fidelity simulation (mannequin with static photo images)
Number of subjects: 45
Study: 17145846

Group type: EXPERIMENTAL
Intervention: Higher mutagen sensitivity (cutoff > or =0.50 breaks per cell)
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Higher IGF-I levels
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Higher IGF-binding protein-3 levels
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: High IGF-I level alone
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: High mutagen sensitivity alone
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Both high IGF-I level and high mutagen sensitivity
Number of subjects: 991
Study: 14747687

Group type: EXPERIMENTAL
Intervention: 300 g of fruits and vegetables
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 600 g of fruits and vegetables
Number of subjects: 12

Group type: COMPARATOR
Intervention: Basic diet (no fruits or vegetables)
Number of subjects: 12
Study: 11763829

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Number of subjects: 170

Group type: COMPARATOR
Intervention: Lifestyle education
Number of subjects: 170
Study: 8529054

Group type: EXPERIMENTAL
Intervention: levodopa (200 mg) + benserazide (50 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 2203517

Group type: EXPERIMENTAL
Intervention: Nilutamide
Number of subjects: 203

Group type: COMPARATOR
Intervention: Castration alone (Placebo)
Number of subjects: 203
Study: 361207

Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (progestogen group)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (placebo group)
Number of subjects: 69
Study: 31185762

Group type: EXPERIMENTAL
Intervention: Cervical Ripening Double Balloon catheter (CRDB)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Foley catheter
Number of subjects: 180
Study: 31655626

Group type: EXPERIMENTAL
Intervention: Lithium plus valproic acid (Li/VPA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Lithium plus carbamazepine (Li/CBZ)
Number of subjects: 64
Study: 27120292

Group type: EXPERIMENTAL
Intervention: (-)-OSU6162 at a dose of 15 mg twice a day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: (-)-OSU6162
Number of subjects: 64
Study: 25520332

Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg
Number of subjects: 344

Group type: COMPARATOR
Intervention: Standard care (fluconazole, liposomal amphotericin B, or caspofungin)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 344
Study: 25675661

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Cold Instruments (CI)
Number of subjects: 130
Study: 22035984

Group type: EXPERIMENTAL
Intervention: MPS silane (ESPE‐Sil, 3M ESPE) applied to all specimens, left to react at 20°C for 2 min, followed by heat treatment at 38°C, 79°C, or 100°C for 1 min.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MPS silane with rinsing in hot water (B groups).
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Heat treatments (G38, G79, G100).
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (GC) received no silane treatment.
Number of subjects: 18
Study: 20705158

Group type: EXPERIMENTAL
Intervention: Contraceptive ring
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Contraceptive patch
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Copper IUC
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Concerns about IUC
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Concerns about infertility and pain with IUC
Number of subjects: 524
Study: 17572147

Group type: EXPERIMENTAL
Intervention: Dofetilide (class III antiarrhythmic)
Number of subjects: 3028

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3028
Study: 15925130

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 498
Study: 12032036

Group type: EXPERIMENTAL
Intervention: Epidural infusion of ropivacaine 1 mg/mL and fentanyl 2 microg/mL with epinephrine 2 microg/mL
Number of subjects: 12

Group type: COMPARATOR
Intervention: Epidural infusion of ropivacaine 1 mg/mL and fentanyl 2 microg/mL without epinephrine
Number of subjects: 12
Study: 9862082

Group type: COMPARATOR
Intervention: 2 mg haloperidol
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5 mg haloperidol
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5 mg d-amphetamine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: d-amphetamine and haloperidol (in smokers subgroup)
Number of subjects: 100
Study: 8908439

Group type: EXPERIMENTAL
Intervention: Argon green laser photocoagulation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 19
Study: 1650128

Group type: EXPERIMENTAL
Intervention: tetravalent rhesus rotavirus vaccine with small-volume (2.5-mL) antacid buffer
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: tetravalent rhesus rotavirus vaccine with large-volume (30-mL) antacid buffer
Number of subjects: 174

Group type: COMPARATOR
Intervention: tetravalent rhesus rotavirus vaccine alone
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: tetravalent rhesus rotavirus vaccine with oral polio vaccine
Number of subjects: 174

Group type: COMPARATOR
Intervention: oral polio vaccine serotype 1
Number of subjects: 174

Group type: COMPARATOR
Intervention: oral polio vaccine serotype 2
Number of subjects: 174

Group type: COMPARATOR
Intervention: oral polio vaccine serotype 3
Number of subjects: 174
Study: 6613137

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 515
Study: 30859967

Group type: EXPERIMENTAL
Intervention: Valbenazine (40mg and 80mg)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Valbenazine (open-label treatment)
Number of subjects: 464
Study: 28857952

Group type: EXPERIMENTAL
Intervention: Instructional method focused on patient status reporting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control instructional method
Number of subjects: 0
Study: 27823710

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) 1000 mg as a single infusion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) 1000 mg
Number of subjects: 32
Study: 25024410

Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) salbutamol provocation at a dosage of 0.30 µg/min for 5 minutes
Number of subjects: 30
Study: 23062392

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 100 μg once daily
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 200 μg once daily
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 300 μg once daily
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 400 μg once daily
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 250 μg twice daily (active control)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 622
Study: 19787464

Group type: EXPERIMENTAL
Intervention: Heated humidifier with conventional microbiologic filter (CMF-HH)
Number of subjects: 41

Group type: COMPARATOR
Intervention: HME-Booster
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both humidifiers (CMF-HH and HME-Booster)
Number of subjects: 41
Study: 17321243

Group type: EXPERIMENTAL
Intervention: Variable-stiffness colonoscope
Number of subjects: 335
Study: 15381545

Group type: EXPERIMENTAL
Intervention: Topical 0.1% tacrolimus ointment plus 308-nm excimer laser therapy (group A)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser monotherapy (group B)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Untreated lesions (control group)
Number of subjects: 14
Study: 11194214

Group type: EXPERIMENTAL
Intervention: 0.5 mg repaglinide at mealtimes (increased to 1 mg after 4 weeks)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study: 9445234

Group type: EXPERIMENTAL
Intervention: Fundoplication and antroplasty
Number of subjects: 15
Study: 9100602

Group type: EXPERIMENTAL
Intervention: hCRH (1 microgram/kg) stimulation alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: hCRH (1 microgram/kg) stimulation with 5% NaCl (0.06 mL.kg/min for 120 min)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Isotonic volume loading (0.9% NaCl, 12 mL.kg.60 min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: hCRH (1 microgram/kg) stimulation
Number of subjects: 14
Study: 2516705

Group type: EXPERIMENTAL
Intervention: Dexamethasone and spironolactone (n = 15)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Spironolactone (n = 10)
Number of subjects: 25
Study: 944395

Group type: EXPERIMENTAL
Intervention: Flufenamic acid (125 mg four to six times per attack)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: COMPARATOR
Intervention: Common antimigraine drugs
Number of subjects: 26
Study: 31537547

Group type: EXPERIMENTAL
Intervention: IL-2 (1 million IU, subcutaneously every other day for 2 weeks, followed by a 2-week break)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31327753

Group type: EXPERIMENTAL
Intervention: Cardiovascular Health Score (CHS) assessment
Number of subjects: 3492

Group type: EXPERIMENTAL
Intervention: Evaluation period since mid-2016
Number of subjects: 3492
Study: 27792991

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 67

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 67
Study: 25450450

Group type: EXPERIMENTAL
Intervention: Unconditional incentive (book voucher mailed with letter of invitation)
Number of subjects: 3334

Group type: EXPERIMENTAL
Intervention: Conditional incentive (book voucher mailed on completion of the online survey)
Number of subjects: 3334

Group type: COMPARATOR
Intervention: Control (no incentive)
Number of subjects: 3334
Study: 24071925

Group type: EXPERIMENTAL
Intervention: Left-shifting prism glasses while standing on the floor (Group 1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Left-shifting prism glasses while on a balance board (Group 2)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Left-shifting prism glasses while on a balance board (Group 3)
Number of subjects: 3
Study: 21353017

Group type: EXPERIMENTAL
Intervention: Epidural analgesia combined with intercostal nerve cryoanalgesia
Number of subjects: 42

Group type: COMPARATOR
Intervention: Epidural analgesia alone
Number of subjects: 42
Study: 20854770

Group type: EXPERIMENTAL
Intervention: Combination of antidepressant medication and cognitive-behavioral therapy focused on suicide prevention (Comb)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy focused on suicide prevention
Number of subjects: 124

Group type: COMPARATOR
Intervention: Antidepressant medication
Number of subjects: 124
Study: 16840826

Group type: EXPERIMENTAL
Intervention: Moderate altitude (MA) group (1700 m)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Low altitude (LA) group (200 m)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study: 12757090

Group type: EXPERIMENTAL
Intervention: 400 microg of intravitreal dexamethasone
Number of subjects: 56

Group type: COMPARATOR
Intervention: No dexamethasone (control group)
Number of subjects: 56
Study: 10794294

Group type: EXPERIMENTAL
Intervention: Ghajar Guide-assisted catheter placement
Number of subjects: 49

Group type: COMPARATOR
Intervention: Freehand catheter placement
Number of subjects: 49
Study: 9340059

Group type: EXPERIMENTAL
Intervention: Symptomatic asthma
Number of subjects: 43

Group type: COMPARATOR
Intervention: Asymptomatic asthma
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sarcoidosis
Number of subjects: 43

Group type: COMPARATOR
Intervention: Allergic alveolitis
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 43
Study: 8324945

Group type: EXPERIMENTAL
Intervention: DAB486IL‐2 (260 kU/kg/d)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: DAB486IL‐2 (130 kU/kg/d)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 3462459

Group type: EXPERIMENTAL
Intervention: Certain therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunophenotype of ALL
Number of subjects: 0
Study: 29678987

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (Octafibrin/Fibryga; Octapharma) - 4g administered within 24 hours of cardiopulmonary bypass
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Cryoprecipitate - 10 units (dose-equivalent to 4g) administered within 24 hours of cardiopulmonary bypass
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (Octafibrin/Fibryga; Octapharma)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Cryoprecipitate
Number of subjects: 1200
Study: 26648582

Group type: EXPERIMENTAL
Intervention: Ascorbic acid-loaded dissolving microneedle patch
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control sample
Number of subjects: 23
Study: 24772989

Group type: EXPERIMENTAL
Intervention: Educational health care package
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 500
Study: 22583983

Group type: EXPERIMENTAL
Intervention: Jerte Valley cherry product
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo product
Number of subjects: 0
Study: 19846474

Group type: EXPERIMENTAL
Intervention: Computer-tailored smoking cessation program
Number of subjects: 194

Group type: COMPARATOR
Intervention: Cluster membership
Number of subjects: 194
Study: 17917552

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 200 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 400 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16095461

Group type: EXPERIMENTAL
Intervention: Unwashed filtered shed blood (USB) return (Group F40)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Leucocyte-reduction filter (LRF) return (Group LRF)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no USB or ABT)
Number of subjects: 48
Study: 12403958

Group type: EXPERIMENTAL
Intervention: 5 mg trafermin
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: 10 mg trafermin
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: 5 mg trafermin (post hoc subgroup analysis)
Number of subjects: 286
Study: 11064879

Group type: EXPERIMENTAL
Intervention: Decision-making and risk-reduction program (workshop lasting one day with five one-hour units)
Number of subjects: 64
Study: 7791258

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.25 mg, administered four times a day from day 18 of the menstrual cycle through day 2 of the next cycle)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (300 mg, administered four times a day from day 18 of the menstrual cycle through day 2 of the next cycle)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo (administered four times a day from day 18 of the menstrual cycle through day 2 of the next cycle)
Number of subjects: 170
Study: 2146357

Group type: EXPERIMENTAL
Intervention: Palpatory pain over osseous structures
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Palpatory pain in paraspinal soft-tissues
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Detection of temperature differences (≥ 1.5 degrees F)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Visual inspection for segmental abnormality
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Active motion palpation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Passive motion palpation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Muscle tension palpation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Misalignment palpation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Composite joint abnormality index (summed positive findings for eight dimensions)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Multidimension index using four most reliable dimensions
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Agreement in lower lumbar spine
Number of subjects: 46
Study: 29779834

Group type: EXPERIMENTAL
Intervention: High-intensity intervention (weekly sessions for 12 months with home-based assessments and advice, n=100)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Low-intensity control (home-based assessments and advice only, n=99)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Conventional group (receiving paediatrician assessment with dietitian input and physical activity/nutrition support, n=44)
Number of subjects: 243
Study: 28782697

Group type: EXPERIMENTAL
Intervention: Brachioradialis release (Group A)
Number of subjects: 74

Group type: COMPARATOR
Intervention: No brachioradialis release (Group B)
Number of subjects: 74
Study: 26303326

Group type: EXPERIMENTAL
Intervention: Standard 40 Hz stimulation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 500 Hz stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1200 Hz stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Burst stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study: 23374024

Group type: EXPERIMENTAL
Intervention: Blocked only
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Random only
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Blocked-then-Random
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Random-then-Blocked
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mixed practice schedules (Blocked-then-Random and Random-then-Blocked)
Number of subjects: 40
Study: 21600592

Group type: EXPERIMENTAL
Intervention: 2-dose methylprednisolone (30 mg/kg per dose, 8 hours preoperatively and operatively)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Single-dose methylprednisolone (30 mg/kg per dose, operatively)
Number of subjects: 76
Study: 19249999

Group type: EXPERIMENTAL
Intervention: RES (Resistance Training)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: RES-C (Resistance Training + Chiropractic Treatment)
Number of subjects: 21
Study: 16977477

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (3.5 mg/day during weeks 1 and 4; 7 mg/day during weeks 2 and 3)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 11
Study: 15267123

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/daily (1000 patients)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Clodronate 100 mg/weekly i.m. (800 patients)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/daily (100 patients)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/daily (100 patients)
Number of subjects: 2000
Study: 11158861

Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.4 mg/d)
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1054
Study: 9258982

Group type: EXPERIMENTAL
Intervention: Oxybutynin 10 mg controlled-release tablet ingested 2 hr after breakfast
Number of subjects: 31

Group type: COMPARATOR
Intervention: Oxybutynin 10 mg controlled-release tablet ingested during fasting
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oxybutynin 10 mg controlled-release tablet ingested 1 hr before breakfast
Number of subjects: 31
Study: 8289615

Group type: COMPARATOR
Intervention: Cyclists (C)
Number of subjects: 16
Study: 3103540

Group type: EXPERIMENTAL
Intervention: PSK combined with Tegafur (FT)
Number of subjects: 3630

Group type: EXPERIMENTAL
Intervention: MMC, FT and PSK
Number of subjects: 3630

Group type: EXPERIMENTAL
Intervention: MMC, FT, PSK and OK-432
Number of subjects: 3630

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy with MMC, FT, PSK and OK-432
Number of subjects: 3630
Study: 31644372

Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 0
Study: 29095201

Group type: EXPERIMENTAL
Intervention: E-Bike
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bike
Number of subjects: 32
Study: 27492018

Group type: EXPERIMENTAL
Intervention: K2 tablet (12.4% w/w Kollidon(®) SR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release tablet (R)
Number of subjects: 0